France is abolishing fixed reimbursement rates for 75 generic drug groups, affecting treatments for diabetes, hypertension, and more, effective October 20, 2026.
CEPS ends fixed reimbursement rates
The Economic Committee for Health Products (CEPS) has decided to end the fixed responsibility rates (TFR) for certain specialities listed in the Generic Drugs Directory. This decision was made on October 7, 2026, after a session on October 1, and it becomes effective on October 20, 2026, following its publication in the Official Journal on October 10.Impact on 75 generic drug groups
The change affects 75 generic drug groups that correspond to 31 international non-proprietary names (DCI). Previously, the TFR set a single reimbursement base for all specialities within a generic group. With its repeal, each affected speciality will now have its own specific reimbursement base, which must be integrated into pharmacy information systems.Wide range of medical conditions covered
The affected medicines are used to treat a variety of medical conditions, including diabetes, hypertension, cardiovascular diseases, infections, digestive disorders, allergies, nervous system conditions, HIV, and eye diseases. The previously fixed reimbursement rates for these drugs ranged from as low as 1 euro for injectable diclofenac to as high as 113.60 euros for efavirenz 600 mg, a 30-tablet box.List of affected generic drugs
The affected generic groups include acarbose, amiloride 5 mg + hydrochlorothiazide 50 mg, amoxicillin 1 g, benazepril, bisoprolol 5 mg, buspirone 10 mg, calcitonin (synthetic salmon) 50 UI/1 ml, carbamazepine 200 mg, cefadroxil, cimetidine, ciprofloxacin 250 mg, sodium diclofenac 75 mg/3 ml, econazole LP 150 mg, efavirenz 600 mg, famotidine, fexofenadine, flutamide 250 mg, glipizide 5 mg, mebverine, mianserine, minocycline, anhydrous nevirapine 200 mg, nifedipine LP, ranitidine, rizatriptan 5 mg, ropinirole, roxithromycin 100 mg, sulpiride, ticlopidine 250 mg, timolol 0.10% (1 mg/0.4 ml), and trandolapril 0.5 mg.
